AAV Bispecific Fusion Vectors for Persistent Anti-Metastatic T Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are not effective for all patients and can have significant adverse side effects, and there is a need for more effective methods to prevent and treat metastasis, particularly targeting circulating tumor cells.
Innovation Solution
Adeno-associated virus (AAV) vectors are used to deliver a bispecific fusion protein that binds to GD2 and CD3, stimulating T cell-mediated killing of tumor cells, thereby reducing the risk of metastasis and treating cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutics are used to treat cancer, then tumor cells can be destroyed, but significant adverse side effects occur and effectiveness is limited
Solution Approach 1:
The patent uses T cells as intermediary agents to kill tumor cells. The bispecific fusion protein acts as a mediator that bridges T cells and GD2+ tumor cells, enabling specific immune-mediated destruction of cancer cells while sparing healthy tissues, thus improving effectiveness and reducing side effects compared to conventional chemotherapeutics
Solution Approach 2:
The patent leverages the patient's own immune system (T cells) to perform the cancer-killing function. By engineering T cells through AAV-mediated gene delivery of the bispecific fusion protein, the body's natural defense mechanisms are enhanced to specifically target and destroy tumor cells, eliminating the need for external toxic chemicals
2Duration of action of stationary object
If AAV vectors are used to deliver bispecific fusion protein for long-term immunologic pressure, then metastasis prevention is improved, but vector complexity and manufacturing difficulty increase
Solution Approach 1:
The AAV vector is designed to perform multiple functions: it delivers the bisspecific fusion protein gene, ensures long-term expression through persistent viral integration, and targets specific cell types. This multi-functionality allows a single vector system to achieve both prolonged immunologic pressure and controlled delivery, balancing persistence with manageable complexity
Solution Approach 2:
The AAV vector is pre-engineered with the complete bispecific fusion protein gene sequence before administration. This preliminary preparation ensures that upon delivery, the vector immediately begins expressing the therapeutic protein, establishing long-term immunologic pressure without requiring complex post-administration manipulation or additional delivery steps
Data Source
AI summary
The disclosure provides recombinant adeno-associated viral (rAAV) vectors expressing a bispecific fusion protein that binds GD2 and CD3, and methods of using the same for reducing the risk of, preventing, or treating metastasis. The disclosure also provides rAAV vectors for expressing the bispecific fusion protein.